Polysaccharide guided tumor delivery of therapeutics: A bio-fabricated galactomannan-gold nanosystem for augmented cancer therapy

Archana, M.G.; Sreekutty, J; Syama, H.P.; Joseph, Manu M.; Anusree, KS; Unnikrishnan, B.S.; Preethi, G. U.; PL, Reshma; Sreelekha, T.T.

doi:10.1016/j.jddst.2023.104172

Cited by 5 publications

(22 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Scheme represents the synthetic route of the HsiRNA@PGD nanoparticles. PSP001-capped gold nanoparticles (PG NPs) and doxorubicin-functionalized PG NPs (PGD NPs) were synthesized as reported earlier . Briefly, 1 mL of 0.5 mg/mL doxorubicin was mixed with the PG NPs solution and was stirred for 24 h at 37 °C.…”

Section: Methodsmentioning

confidence: 99%

“…We have already established the relationship between gold nanoparticles and PSP001 as a promising drug delivery method . Having recognized the potential of the above-mentioned nanoparticles, in the current investigations, we bring forth the PSP001-coated gold nanoparticles to deliver siRNA against HER2 protein and doxorubicin (DOX) as an anticancer medication for treating HER2-positive breast cancer both in vitro and in vivo .…”

Section: Introductionmentioning

confidence: 91%

“…Additionally, quantitative apoptosis analysis was carried out employing the Muse Annexin V and dead cell kit (Merck Millipore) as per the instructions of manufacturers as described previously. 33 The Muse cell analyzer was used to calculate the percentage of apoptotic cells.…”

Section: Validation Of Binding Efficiencymentioning

confidence: 99%

“…33 Thus, gold nanoparticles (NPs) coated with PSP001 are an example of such a system, which could be exploited to deliver siRNA against the HER2 protein, as well as the anticancer medication doxorubicin, for the management of breast cancer. 33 This method takes advantage of the enhanced permeation and retention effect (EPR) effect to passively accumulate the NPs in the tumor and protect the siRNA from degradation in an acidic endosomal environment while also delivering the medicine and gene specifically to the target tumor cells. 42,43 Overall, the development of nanotechnology-based delivery platforms is a powerful tool to increase the therapeutic index of traditional medicines while limiting potential side effects.…”

Section: Introductionmentioning

confidence: 99%

“…Polysaccharides are biodegradable, meaning they can be enzymatically or chemically degraded in the body into nontoxic byproducts, which are easily eliminated and generally exhibit low immunogenicity, reducing the risk of immune responses or clearance by the reticuloendothelial system (RES). The polysaccharide PSP001, isolated from the fruit rind of Punca granatum (pomegranate), was extensively studied by our group for its excellent anticancer, antimetastatic, antioxidant, and immunomodulatory potentials. − PSP001 was subjected to the fabrication of many types of nanoparticles including gold, silver, and much more from our group. ,− Our laboratory has already proved the efficiency of polysaccharide PSP001 as reducing and capping agent of gold nanoparticles . Thus, gold nanoparticles (NPs) coated with PSP001 are an example of such a system, which could be exploited to deliver siRNA against the HER2 protein, as well as the anticancer medication doxorubicin, for the management of breast cancer .…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

HER2 siRNA Facilitated Gene Silencing Coupled with Doxorubicin Delivery: A Dual Responsive Nanoplatform Abrogates Breast Cancer

M. G.,

K. S.,

B. S.

et al. 2024

ACS Appl. Mater. Interfaces

Self Cite

View full text Add to dashboard Cite

The present study investigated the concurrent delivery of antineoplastic drug, doxorubicin, and HER2 siRNA through a targeted theranostic metallic gold nanoparticle designed using polysaccharide, PSP001. The as-synthesized HsiRNA@PGD NPs were characterized in terms of structural, functional, physicochemical, and biological properties. HsiRNA@PGD NPs exposed adequate hydrodynamic size, considerable ζ potential, and excellent drug/siRNA loading and encapsulation efficiency. Meticulous exploration of the biocompatible dual-targeted nanoconjugate exhibited an appealing biocompatibility and pH-sensitive cargo release kinetics, indicating its safety for use in clinics. HsiRNA@PGD NPs deciphered competent cancer cell internalization, enhanced cytotoxicity mediated via the induction of apoptosis, and excellent downregulation of the overexpressing target HER2 gene. Further in vivo explorations in the SKBR3 xenograft breast tumor model revealed the appealing tumor reduction properties, selective accumulation in the tumor site followed by significant suppression of the HER2 gene which contributed to the exclusive abrogation of breast tumor mass by the HsiRNA@PGD NPs. Compared to free drugs or the monotherapy constructs, the dual delivery approach produced a synergistic suppression of breast tumors both in vitro and in vivo. Hence the drawings from these findings implicate that the as-synthesized HsiRNA@PGD NPs could offer a promising platform for chemo-RNAi combinational breast cancer therapy.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 91%

Section: Validation Of Binding Efficiencymentioning

confidence: 99%